Driver Brandon R, Barrios Roberto, Ge Yimin, Haque Abida, Tacha David, Cagle Philip T
From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Drs Driver, Barrios, Ge, Haque, and Cagle); and Biocare Medical LLC, Concord, California (Dr Tacha).
Arch Pathol Lab Med. 2016 Jul;140(7):682-5. doi: 10.5858/arpa.2015-0431-OA. Epub 2015 Nov 24.
-Folate receptor α (FRA) is a glycosylphosphatidylinositol-anchored high-affinity folate receptor that localizes to the apical surface of epithelia when it is expressed in normal tissue. Unlike normal tissues, FRA may localize to the basolateral side in tumors. These features make FRA an attractive drug target, and several FRA-targeted drugs have been developed and are in phases of clinical testing. Folate receptor α protein expression shows intertumoral variability that may correlate with response to therapy and to clinicopathologic parameters. Using immunohistochemistry, a recent study of breast carcinomas found FRA protein expression was associated with triple-negative status and high histologic grade in breast cancer. Although a prior study of lung adenocarcinomas found the expression level of the gene encoding FRA, FOLR1, was significantly increased in low-histologic-grade tumors compared to high-histologic-grade tumors, the relationship between FRA protein expression and histologic grade has not been reported for lung adenocarcinomas.
-To investigate the relationship between FRA protein expression level and clinicopathologic parameters in lung adenocarcinomas, including histologic grade, by performing immunohistochemistry for FRA on a cohort of non-small cell lung carcinomas.
-High-density tissue microarrays constructed from 188 non-small cell lung carcinomas and used in prior studies were immunostained with FRA-specific antibody clone 26B3. Folate receptor α membranous staining intensity was given a semiquantitative score from 0 to 3+ for triplicate cores of tumor and averaged for each tumor. An average semiquantitative score from 0 to 1.4 was considered low expression, and an average semiquantitative score greater than 1.4 was considered high expression.
-The majority (60 of 78; 77%) of lung adenocarcinomas and a minority (4 of 41; 10%) of lung squamous cell carcinomas were positive for FRA. Folate receptor α expression in lung adenocarcinomas compared with squamous cell carcinomas was statistically different (P < .001, χ(2) test). In lung adenocarcinomas, FRA expression level correlated with histologic grade (P = .005, χ(2) test for trend), but no other clinicopathologic parameter. The majority (23 of 27; 85%) of grade 1 adenocarcinomas had high FRA protein expression, whereas approximately half of grade 2 (10 of 19; 53%) and grade 3 (12 of 25; 48%) adenocarcinomas had high FRA protein expression. Out of adenocarcinomas with lepidic growth pattern, 16 of 20 (80%) showed high FRA protein expression. Out of adenocarcinomas with solid growth pattern, 2 of 6 (33%) showed high FRA protein expression. In lung adenocarcinomas, FRA expression level did not correlate with thyroid transcription factor 1, napsin A, or survival.
-Folate receptor α protein was expressed in the majority of lung adenocarcinomas and a minority of lung squamous cell carcinomas. Folate receptor α protein expression correlated with histologic grade for lung adenocarcinomas, and the greatest difference was observed between grade 1 and grade 3. Our results indicate that poorly differentiated adenocarcinomas or focuses of poor differentiation in a heterogeneous tumor may lack FRA protein expression and be more likely to be resistant to FRA-targeting drugs.
-叶酸受体α(FRA)是一种糖基磷脂酰肌醇锚定的高亲和力叶酸受体,在正常组织中表达时定位于上皮细胞的顶端表面。与正常组织不同,FRA在肿瘤中可能定位于基底外侧。这些特性使FRA成为一个有吸引力的药物靶点,并且已经开发了几种靶向FRA的药物,它们正处于临床试验阶段。叶酸受体α蛋白表达存在肿瘤间变异性,这可能与治疗反应和临床病理参数相关。一项最近对乳腺癌的研究使用免疫组织化学方法发现,FRA蛋白表达与乳腺癌的三阴性状态和高组织学分级相关。尽管先前一项对肺腺癌的研究发现,与高组织学分级肿瘤相比,编码FRA的基因FOLR1在低组织学分级肿瘤中的表达水平显著升高,但尚未有关于肺腺癌中FRA蛋白表达与组织学分级之间关系的报道。
-通过对一组非小细胞肺癌进行FRA免疫组织化学检测,研究肺腺癌中FRA蛋白表达水平与临床病理参数(包括组织学分级)之间的关系。
-由188例非小细胞肺癌构建的高密度组织芯片,这些组织芯片曾用于先前的研究,用FRA特异性抗体克隆26B3进行免疫染色。对肿瘤的三个重复核心的叶酸受体α膜染色强度给予0至3+的半定量评分,并对每个肿瘤进行平均。平均半定量评分在0至1.4之间被认为是低表达,大于1.4的平均半定量评分被认为是高表达。
-大多数(78例中的60例;77%)肺腺癌和少数(41例中的4例;10%)肺鳞状细胞癌FRA呈阳性。肺腺癌中叶酸受体α的表达与鳞状细胞癌相比有统计学差异(P <.001,χ²检验)。在肺腺癌中,FRA表达水平与组织学分级相关(P =.005,趋势χ²检验),但与其他临床病理参数无关。大多数(27例中的23例;85%)1级腺癌有高FRA蛋白表达,而大约一半的2级(19例中的10例;53%)和3级(25例中的12例;48%)腺癌有高FRA蛋白表达。在具有鳞屑样生长模式的腺癌中,20例中的16例(80%)显示高FRA蛋白表达。在具有实体生长模式的腺癌中,6例中的2例(33%)显示高FRA蛋白表达。在肺腺癌中,FRA表达水平与甲状腺转录因子1、 napsin A或生存率无关。
-叶酸受体α蛋白在大多数肺腺癌和少数肺鳞状细胞癌中表达。叶酸受体α蛋白表达与肺腺癌的组织学分级相关,在1级和3级之间观察到最大差异。我们的结果表明,低分化腺癌或异质性肿瘤中的低分化灶可能缺乏FRA蛋白表达,并且更有可能对靶向FRA的药物耐药。